Skip to content

Comment on “Prophylactic Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Women With Placenta Previa: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial”

Nov 2026 · Obstetrical & Gynecological Survey · 0 citations

Abstract

Placenta previa increases the risk of postpartum hemorrhage (PPH), which has been associated with >20% of maternal deaths worldwide. In China, the prevalence of placenta previa increased 3-fold after the universal two-child policy was implemented. Tranexamic acid (TXA) has been used to treat PPH during cesarean delivery. However, there has been limited evidence about its prophylactic use in high-risk patients. The aim of this study was to evaluate whether TXA given during cesarean delivery could reduce PPH in women with placenta previa. This was a randomized, double-blind, placebo-controlled, phase 3 trial, conducted in 24 hospitals across 10 Chinese provinces from July 2023 to March 2025. Included were adult patients with singleton or multiple pregnancy at ≥34 weeks of gestation, who underwent cesarean delivery. Excluded were those with thromboembolic risk factors, history of epilepsy or seizures, active malignancy, cardiovascular disorders, kidney or liver dysfunction, autoimmune diseases, or hypersensitivity to TXA. Participants were randomly assigned to receive either 1 g of intravenous TXA or a placebo within 5 minutes after the umbilical cord was clamped. Both groups also received prophylactic oxytocin after delivery. The primary outcome was PPH, defined as a calculated blood loss ≥1000 mL or a red blood cell transfusion within 2 days after delivery. A total of 1694 patients were included in the analysis, with 845 in the TXA group and 849 in the placebo group. PPH occurred less often in patients given TXA than those who received the placebo [29.7% vs. 35.1%; relative risk (RR), 0.85; 95.2% CI: 0.75-0.96; P =0.01]. Estimated blood loss of ≥1000 mL occurred in 25.7% and 31.6% of patients, respectively (RR, 0.81; 95% CI: 0.70-0.93). Red blood cell transfusion occurred in 18.8% of the TXA group and 21.6% of the placebo group (RR, 0.88; 95% CI: 0.74-1.03). Serious adverse events occurred in 0.5% of each group (RR, 1.01; 95% CI: 0.25-4.00). In women with placenta previa undergoing cesarean delivery, prophylactic TXA produced a statistically significant but modest reduction in PPH without an observed increase in serious adverse events. (Summarized from Zhang L, Bi S, Chen L, et al. Prophylactic tranexamic acid for the prevention of postpartum haemorrhage in women with placenta praevia: multicentre, double blind, randomised, placebo controlled, phase 3 trial. BMJ . 2026;392:e089636. doi:10.1136/bmj-2026-089636)

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.